ASCAT 2024 | Congenital amegakaryocytic thrombocytopenia: what is it and should transplantation be considered?
Jean-Hugues Dalle
• 3 Oct 2024
Jean-Hugues Dalle, MD, PhD, Université Paris Cité, Paris, France, discusses congenital amegakaryocytic thrombocytopenia, a rare inherited bone marrow failure disorder in which patients lack platelets and are at risk of severe hemorrhagic conditions. Prof. Dalle emphasizes that stem cell transplantation is the only curative therapy and should be considered for patients, especially those who are young. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: Vertex.
